UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients

Inflammatory intestinal diseases, 2021-09, Vol.6 (3), p.165-174

2021

Link zum Volltext

Verfügbarkeit prüfen

Epidemiology of Eosinophilic Esophagitis

Digestive diseases (Basel), 2014, Vol.32 (1-2), p.40-47

Hruz, Petr

2014

Link zum Volltext

Verfügbarkeit prüfen

Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients

Inflammatory intestinal diseases, 2018-03, Vol.2 (3), p.171-179

2018

Link zum Volltext

Verfügbarkeit prüfen

Defer No Time, Delays Have Dangerous Ends (William Shakespeare)

Gastroenterology (New York, N.Y. 1943), 2021-07, Vol.161 (1), p.42-44

2021

Link zum Volltext

Verfügbarkeit prüfen

Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently

Clinical pharmacokinetics, 2022-07, Vol.61 (7), p.1039-1055

2022

Link zum Volltext

Verfügbarkeit prüfen

Mo1146 – Clinical Manifestation, Course of Disease and Evaluation of Treatment Response Including Vedolizumab in a Large Swiss Case Series of Eosinophilic Gastroenteritis Patients

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-722-S-722

2019

Link zum Volltext

Verfügbarkeit prüfen

Su1850 MISMATCH IN PHYSICIAN AND PATIENT PERCEPTION OF FECAL URGENCY AND INCONTINENCE IN INFLAMMATORY BOWEL DISEASE - RESULTS FROM THE FECAL URGENCY SURVEY

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-843-S-844

2024

Link zum Volltext

Verfügbarkeit prüfen

Mo1758 FEASIBILITY STUDY OF A POINT-OF-CARE ASSAY FOR RAPID DETERMINATION OF ANTI-TNFA BIOLOGICS IN CAPILLARY BLOOD

Gastroenterology (New York, N.Y. 1943), 2024-05, Vol.166 (5), p.S-1100-S-1100

2024

Link zum Volltext

Verfügbarkeit prüfen

Mo1882 – Immune Cell and Checkpoint Signatures in Pbmc of Patients with Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-873-S-874

2019

Link zum Volltext

Verfügbarkeit prüfen

Su1873 – Remission to Vedolizumab is Not Higher in TNF-Naive Compared to TNF-Pretreated Patients with Crohn’s Disease

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-645-S-645

2019

Link zum Volltext

Verfügbarkeit prüfen

Exercise-induced Chest Pain: An Atypical Manifestation of Eosinophitic Esophagitis

The American journal of medicine, 2015-02, Vol.128 (2), p.196

2015

Link zum Volltext

Verfügbarkeit prüfen

881: BUDESONIDE ORODISPERSIBLE TABLETS MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWING THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Gastroenterology (New York, N.Y. 1943), 2022-05, Vol.162 (7), p.S-213-S-213

2022

Link zum Volltext

Verfügbarkeit prüfen

Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients

Cancer Immunology, Immunotherapy, 2023-07, Vol.72 (7), p.2003-2004

2023

Link zum Volltext

Verfügbarkeit prüfen

AS036 - AXL-expressing homeostatic liver macrophages are reduced in patients with progression of cirrhosis

Journal of hepatology, 2020-08, Vol.73, p.S30-S31

2020

Link zum Volltext

Verfügbarkeit prüfen

AXL-expressing homeostatic liver macrophages are reduced in patients with progression of cirrhosis

Journal of hepatology, 2020-08, Vol.73, p.S30-S31

2020

Link zum Volltext

Verfügbarkeit prüfen

Mo1129 – Efficacy of Budesonide Orodispersible Tablets for Induction of Remission in Patients with Active Eosinophilic Esophagitis: Results from the 6-Weeks Open-Label Treatment Phase of Eos-2 Trial

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-715-S-715

2019

Link zum Volltext

Verfügbarkeit prüfen

951a – Budesonide Orodispersible Tablets are Highly Effective to Maintain Clinico-Histological Remission in Adult Patients with Eosinophilic Esophagitis: Results from the 48-Weeks, Double-Blind, Placebo-Controlled, Pivotal Eos-2 Trial

Gastroenterology (New York, N.Y. 1943), 2019-05, Vol.156 (6), p.S-1509-S-1509

2019

Link zum Volltext

Verfügbarkeit prüfen

Tu1114 Familial Eosinophilic Esophagitis (EoE) Uncovers a New EoE-Like Syndrome Without Tissue Eosinophilia

Gastroenterology (New York, N.Y. 1943), 2015-04, Vol.148 (4), p.S-791-S-791

2015

Link zum Volltext

Verfügbarkeit prüfen

β 6 -integrin serves as a novel serum tumor marker for colorectal carcinoma

International journal of cancer, 2019-08, Vol.145 (3), p.678-685

2019

Link zum Volltext

Verfügbarkeit prüfen

AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate CellsSummary

Cellular and molecular gastroenterology and hepatology, 2023-01, Vol.16 (1), p.17-37

2023

Link zum Volltext

Verfügbarkeit prüfen

Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's disease

Nature medicine, 2019-04, Vol.25 (4), p.701-701

2019

Link zum Volltext

Verfügbarkeit prüfen

High Prevalence of Vitamin D Deficiency among Patients with Inflammatory Bowel Disease

Inflammatory intestinal diseases, 2018-07, Vol.2 (4), p.200-210

2018

Link zum Volltext

Verfügbarkeit prüfen

Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice

Communications biology, 2020, Vol.3, p.130

2020

Link zum Volltext

Verfügbarkeit prüfen

M1795 Protein Tyrosine Phosphatase N2 Regulates Ifngamma-Induced Cytokine Signalling in THP-1 Monocytes

Gastroenterology (New York, N.Y. 1943), 2010, Vol.138 (5), p.S-420-S-421

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 48

Suche als RSS-Feed

Aktive Filter

ThemaScience & Technology

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(44)

Publikationsform

Sprache

Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients

Epidemiology of Eosinophilic Esophagitis

Low Discontinuation Rate of Infliximab Treatment in Steroid-Dependent/Refractory Crohn’s Disease Patients

Defer No Time, Delays Have Dangerous Ends (William Shakespeare)

Liver Cirrhosis Affects the Pharmacokinetics of the Six Substrates of the Basel Phenotyping Cocktail Differently

Mo1146 – Clinical Manifestation, Course of Disease and Evaluation of Treatment Response Including Vedolizumab in a Large Swiss Case Series of Eosinophilic Gastroenteritis Patients

Su1850 MISMATCH IN PHYSICIAN AND PATIENT PERCEPTION OF FECAL URGENCY AND INCONTINENCE IN INFLAMMATORY BOWEL DISEASE - RESULTS FROM THE FECAL URGENCY SURVEY

Mo1758 FEASIBILITY STUDY OF A POINT-OF-CARE ASSAY FOR RAPID DETERMINATION OF ANTI-TNFA BIOLOGICS IN CAPILLARY BLOOD

Mo1882 – Immune Cell and Checkpoint Signatures in Pbmc of Patients with Ulcerative Colitis

Su1873 – Remission to Vedolizumab is Not Higher in TNF-Naive Compared to TNF-Pretreated Patients with Crohn’s Disease

Exercise-induced Chest Pain: An Atypical Manifestation of Eosinophitic Esophagitis

881: BUDESONIDE ORODISPERSIBLE TABLETS MAINTAIN CLINICAL, HISTOLOGICAL AND ENDOSCOPIC REMISSION IN ADULT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 96-WEEKS OPEN-LABEL EXTENSION PHASE FOLLOWING THE 1-YEAR DOUBLE-BLIND EOS-2 TRIAL

Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients

β6‐integrin serves as a novel serum tumor marker for colorectal carcinoma

AS036 - AXL-expressing homeostatic liver macrophages are reduced in patients with progression of cirrhosis

AXL-expressing homeostatic liver macrophages are reduced in patients with progression of cirrhosis

Mo1129 – Efficacy of Budesonide Orodispersible Tablets for Induction of Remission in Patients with Active Eosinophilic Esophagitis: Results from the 6-Weeks Open-Label Treatment Phase of Eos-2 Trial

951a – Budesonide Orodispersible Tablets are Highly Effective to Maintain Clinico-Histological Remission in Adult Patients with Eosinophilic Esophagitis: Results from the 48-Weeks, Double-Blind, Placebo-Controlled, Pivotal Eos-2 Trial

Tu1114 Familial Eosinophilic Esophagitis (EoE) Uncovers a New EoE-Like Syndrome Without Tissue Eosinophilia

β 6 -integrin serves as a novel serum tumor marker for colorectal carcinoma

AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate CellsSummary

Publisher Correction: Microbial network disturbances in relapsing refractory Crohn's disease

High Prevalence of Vitamin D Deficiency among Patients with Inflammatory Bowel Disease

Loss of the branched-chain amino acid transporter CD98hc alters the development of colonic macrophages in mice

M1795 Protein Tyrosine Phosphatase N2 Regulates Ifngamma-Induced Cytokine Signalling in THP-1 Monocytes

Aktive Filter

Suchergebnisse filtern